Navigation Links
A Combined Heart Pill-developed by Dr. Reddy’

Dr. Reddy’s, the Indian pharma giant has decided to join hands with the University of Auckland, //New Zealand to begin Global trials of a new fixed dose combination or “polypills” to prevent strokes and heart attacks.

The polypill will combine four drugs- aspirin, statin(to reduce cholesterol) and two drugs to prevent hypertension. The trial will check the reliability of the pill when it comes to safety and its effectiveness when consumed as one pill.

Investments of Dr. Reddy’s in the trial would come up to $7.5 million, and The Health Research Council, New Zealand has invested U.S. $241,055.

Dr. Reddy’s has initiated the trial six months ago, Satish Reddy, COO and managing director of Dr. Reddy’s said, “Since all medicines in the polypill are already prescribed to heart attack patients, we don’t anticipate any problem with polypill trial.”

Anyway, the plan of having a global trial will assess the success of using the polypill in different populations. The trial will begin by the second quarter of 2007, and would involve 600 people from five continents.

Apart from people from India and New Zealand, the other countries involved in the global trial would be South Africa, China, Australia, Brazil, the United Kingdom and the United States.

It took three years for the drug company to formulate this pill. Mr.Reddy’s claims this pill to be “single most important initiative of the decade” by his firm. He also said, “We should be able to introduce the drug for secondary indication [prescriptions to stroke/heart attack patients] by mid-2007.”

Affordability of the polypill

The cost of this pill is taken to prime importance since it is to be used in developing countries. Dr.Reddy’s assured, “Our intention is to see that one month’s medication costs less than Rs. 100 [U.S. $2.20]. The combination is not going to bring us big money, but it will help the patients as they get all four pills co mbined.”

Trials at Global Level

Professor Anthony Rodgers working at the University of Auckland’s, belonging to the clinical trials research unit is going to lead the trial. He has been an advisory to WHO and is also a world-renowned clinical trial expert.

Prof. Rodgers claims that this combined pill will prove to be more effective than four medicines. He said, “Research shows that people with chronic diseases, like heart disease, take only half their medications, they forget, or they feel well, so think they don’t need to take their pills. However, that creates a gap in their treatment, which can have serious consequences for some patients.”

Thus he believes that this oil is a more practical and easy solution to cardiac ailments.

Prof. Rodgers said that the first trial would involve 5000 people moderately prone to cardiac ailments. He said, “The first trial will confirm whether the polypill lowers blood pressure and cholesterol, if it goes ahead, this second trial would confirm the pill’s ability to prevent heart attacks and strokes.”
Source-Medindia
KOM
'"/>




Related medicine news :

1. Combined scan gives exact cancer diagnosis
2. A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss
3. Combined modality approach for effective treatment and enhanced survival in bile duct cancer
4. Vision Loss in Elderly Caused By Combined Effect of Genes and Bacterium
5. Exercise Combined with Dialysis Yields Better Results
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. A Combined Research for Producing Chlamydia Vaccine Begins
8. Combined Ingredients may Cut Cholesterol Levels
9. Combined Imaging Approach may Provide Better Identification of Difficult-to-diagnose Brain Clots
10. Combined Imaging Approach may Be Effective in Diagnosing Some Brain Clots
11. One in Three Heart Attack Patients Have No Chest Pains
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... ... weight management program at Women’s Excellence will help patients lose weight and keep ... exam. The specialists at Women's Excellence will measure BMI, body fat composition, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... nurses and supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. ... Bundles.” , “Increasingly, supply chain and value analysis professionals have a ‘seat ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is ... complicated and require expert user knowledge. In a live webinar on April 11th ... simplified, yet highly accurate, determination of sodium. , It has long been known ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in ... Bill (AB) 1512, which proposes a tax on prescription opioids to fund drug ...
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for ... , All through the year, Garden Media aims to provide material helpful to ... influencers and pitching client’s key messages to gain coveted media placements, Garden ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
Breaking Medicine Technology: